<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02621333</url>
  </required_header>
  <id_info>
    <org_study_id>HenanCH003</org_study_id>
    <nct_id>NCT02621333</nct_id>
  </id_info>
  <brief_title>Chemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV EGFR-wild Type Lung Adenocarcinoma</brief_title>
  <official_title>Chemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV EGFR-wild Type Lung Adenocarcinoma: A Prospective, Randomised, Open, Multicenter Phase Ⅱ Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Henan Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hebei Medical University Fourth Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanxi Dayi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tangshan People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>150th Hospital of PLA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Nanyang Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanyang Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First People's Hospital of Shangqiu</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Anyang Regional Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Puyang Oil Field General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shenma Medical Group General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jiaozuo Tumor Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The 152th Central Hospital of PLA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xinyang Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Henan Cancer Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized, open, multicenter phase Ⅱ study to evaluate the efficacy
      of cytokine-induced killer cells combined chemotherapy in stage Ⅳ naive EGFR wild-type lung
      adenocarcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is still no great improvement in advanced EGFR wild-type lung adenocarcinoma although
      great progress was made in treatment of non-small cell lung cancer. It's necessary to explore
      the treatment mode of this kind of patients. As the progress was made in tumor immunity and
      immunotherapy, more and more cancer therapists accept the treatment model of chemotherapy
      combined immunotherapy. And now chemotherapy combined autologous CIK cells is one kind of
      common treatment model in some countries. Investigators try to evaluate the efficacy and
      safety of this kind of treatment model in patients with stage Ⅳ naive EGFR wild-type lung
      adenocarcinoma.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival time</measure>
    <time_frame>from the day of randomization to the day of death, up to 36 months</time_frame>
    <description>overall survival time aims at from date of randomization until the date of death from any cause, up to 36 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>time to progression</measure>
    <time_frame>from the day of randomization to the day of first detecting progression, up to 24 months</time_frame>
    <description>time to progression points to from date of randomization until the date of first documented progression, up to 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>objective response rate</measure>
    <time_frame>one year</time_frame>
    <description>the partion of overall remission in total proportion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Lung Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>CIK combined chemotherapy group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>autologous CIK combined chemotherapy group Drugs: platinum combined doublets; After 3 or 4 days of chemotherapy, about 5×109 autologous cytokine-indued killer cells are transfused into the vein of patients in one hour.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>chemotherapy group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>platinum combined doublets Drugs: Paclitaxel 175mg/m2 D1, or Docetaxel75mg/m2 D1, or Pemetrexed Disodium 500mg/m2，D1；combined cisplatin 25mg/ m2，D1-3 or carboplatin AUC=5, D1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CIK</intervention_name>
    <description>platinum combined doublets: Paclitaxel 175mg/m2 D1, or Docetaxel75mg/m2 D1, or Pemetrexed Disodium 500mg/m2，D1；combined cisplatin 25mg/m2，D1-3 or carboplatin AUC=5, D1. After 3 or 4 days of chemotherapy, about 5×109 autologous cytokine-induced killer cells are transfused into the vein of patients in one hour.</description>
    <arm_group_label>CIK combined chemotherapy group</arm_group_label>
    <other_name>autologous cytokine-induced killer cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chemotherapy</intervention_name>
    <description>platinum combined doublets: Paclitaxel 175mg/m2 D1, or Docetaxel75mg/m2 D1, or Pemetrexed Disodium 500mg/m2，D1；combined cisplatin 25mg/m2，D1-3 or carboplatin AUC=5, D1.</description>
    <arm_group_label>CIK combined chemotherapy group</arm_group_label>
    <arm_group_label>chemotherapy group</arm_group_label>
    <other_name>platinum combined doublets</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosed as stage Ⅳ naive EGFR wild-type lung adenocarcinoma by image, tissue and/or
             cytology; or relapse after operation (if the patient received adjuvant chemotherapy
             and the interval between the last chemotherapy and relapse is at least six months. The
             detection method of EGFR mutation is ARMS.

          2. EML4-ALK fuse gene is negative and the detection of EML4-ALK is FISH or ventana IHC.

          3. There should be at least one measurable lesions (by CT or MRI)

          4. No other cancer history ( except skin squamous cell carcinoma after surgery)

          5. Age between 18 and 75 years old

          6. World health organization- Eastern Cooperative Oncology Group Performance Status 0-1

          7. Life expectancy more than 3 months and can be followed-up

          8. Patients must have adequate organ and marrow functions as defined below: white blood
             cells: more than 3.5×109/L, Neutrophils: more than 1.5×109/L, Platelets: more than
             80×109/L, Hemoglobin more than 90g/L, Serum total bilirubin less than 1.5 folds of the
             upper normal limit (ULN), Serum glutamic-oxal

             (o) acetic transaminase: less than 2.5×ULN (if there is liver metastasis less than
             5×ULN); Serum creatinine: less than 1.0×ULN, Prothrombin time, Active partial
             thromboplastin time, Fibrinogen, Thrombin time are in normal ranges.

          9. Women of child-bearing period must take effective contraceptive measures during all
             the time of study. During the period of study the results of blood and urine pregnancy
             test should be negative.

         10. Men should take effective contraceptive measures from the beginning of therapy to one
             month after the last cycle of chemotherapy.

         11. Willing to comply with the ban and constraints for this study protocol specified.

         12. Informed consent and willing to participate in this study.

        Exclusion Criteria:

          1. Accepted other study drugs 30 days before the beginning of this study.

          2. Brain metastases with clinical symptoms ( with exception of being controlled after
             radiation)

          3. Active viral or bacterial infection and can't be controlled with appropriate
             anti-infection treatment

          4. Known as HIV infection, syphilis serology reaction positive, active hepatitis B virus
             or hepatitis C virus infection

          5. Suffering from mental illness or other illness, such as heart or lung disease,
             diabetes, etc. that can not be controlled, and can not be coped with study treatment
             and monitoring requirements.

          6. Known allergy to any kind of component of study drugs

          7. Active rheumatic diseases

          8. Organ transplant recipients

          9. Poor compliance

         10. Pregnant women

         11. Lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Quanli Gao, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Henan Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Quanli Gao, M.D.</last_name>
    <phone>+86-371 65587795</phone>
    <email>gaoquanli2015@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lingdi Zhao, M.D.</last_name>
    <phone>+86-371 65587483</phone>
    <email>lingdi1010@sohu.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university</name>
      <address>
        <city>ZhengZhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Quanli Gao, M.D.</last_name>
      <phone>+8615038171966</phone>
      <email>guaoquanli2015@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Lingdi Zhao, M.D.</last_name>
      <phone>+8637165587483</phone>
      <email>lingdi1010@sohu.com</email>
    </contact_backup>
    <investigator>
      <last_name>Quanli Gao, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Li R, Wang C, Liu L, Du C, Cao S, Yu J, Wang SE, Hao X, Ren X, Li H. Autologous cytokine-induced killer cell immunotherapy in lung cancer: a phase II clinical study. Cancer Immunol Immunother. 2012 Nov;61(11):2125-33. doi: 10.1007/s00262-012-1260-2. Epub 2012 May 13.</citation>
    <PMID>22581306</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhong R, Teng J, Han B, Zhong H. Dendritic cells combining with cytokine-induced killer cells synergize chemotherapy in patients with late-stage non-small cell lung cancer. Cancer Immunol Immunother. 2011 Oct;60(10):1497-502. doi: 10.1007/s00262-011-1060-0. Epub 2011 Jun 17.</citation>
    <PMID>21681372</PMID>
  </results_reference>
  <results_reference>
    <citation>Wang S, Wang Z. Efficacy and safety of dendritic cells co-cultured with cytokine-induced killer cells immunotherapy for non-small-cell lung cancer. Int Immunopharmacol. 2015 Sep;28(1):22-8. doi: 10.1016/j.intimp.2015.05.021. Epub 2015 May 23. Review.</citation>
    <PMID>26013109</PMID>
  </results_reference>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 25, 2015</study_first_submitted>
  <study_first_submitted_qc>December 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2015</study_first_posted>
  <last_update_submitted>December 2, 2015</last_update_submitted>
  <last_update_submitted_qc>December 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Henan Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Quanli Gao</investigator_full_name>
    <investigator_title>director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

